ODE (Office of Device Evaluation) strives for empathetic approach to industry
This article was originally published in Clinica
Executive Summary
Much to the relief of industry, the days of intimidation are on the way out at the US FDA's office of device evaluation (ODE). Since taking over as ODE director last summer, Bernard Statland has been striving to alter his staff's previously adversarial stance towards industry to what he describes as "closer to a collaborative relationship."